Anderson, G. D., Lin, Y. X., Berge, C. and Ojemann, G. A. (1997). Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg., 87,252-256.

Bähr O., Hermisson M., Rona S., Rieger J., Nussbaum S., Körtvelyessy P., Franz K.,Tatagiba M., Seifert V., Weller M., Steinbach J.P.(2012).Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochir (Wien). ,154(2),229-35. discussion 235.

Berendsen S., Broekman M., Seute T., Snijders T., van Es C., de Vos F., Regli L., Robe P. (2012). Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9),1391-415. doi: 10.1517/13543784.2012.694425.

Brodie, M. J., Mintzer, S., Pack, A. M., Gidal, B. E., Vecht, C. J. and Schmidt, D. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia, 54,11-27.

Chang E.F., Potts M.B., Keles G.E., Lamborn K.R., Chang S.M., Barbaro N.M., Berger M.S. (2008). Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg.,108(2),227-35.

Dinapoli, L., Maschio, M., Jandolo, B., Fabi, A., Pace, A., Sperati, F. and Muti, P.(2009) Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. Neurol Sci.,30,353-359.

Englot, D.J., et al., Seizures in supratentorial meningioma: a systematic review and meta-analysis. J Neurosurg, 2016. 124(6): p. 1552-61. DOI: 10.3171/2015.4.jns142742. Pubmed PMID: 26636386

Happold, C., Gorlia, T., Chinot, O., Gilbert, M. R., Nabors, L. B., Wick, W., . . . Weller, M. (2016). Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. J Clin Oncol, 34(7), 731-739. doi: 10.1200/jco.2015.63.6563

Kerrigan, S. and Grant, R. (2011). Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst Rev 2011; CD008586.

Knudsen-Baase, K. M., Engeland, A., Gilhus, N. E., Storstein, A. M., & Owe, J. F. (2016). Does the choice of antiepileptic drug affect survival in glioblastoma patients? Journal of Neuro-Oncology, 129(3), 461-469

Lim D.A., Tarapore P., Chang E., Burt M., Chakalian L., Barbaro N., Chang S., Lamborn K.R., McDermott M.W. (2009). Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol., 93(3),349-54.

Lu Y, Yu W, Wang X. (2009). Efficacy of topiramate in adult patients with symptomatic epilepsy: an open-label, long-term, retrospective observation. CNS Drugs, 23(4),351-9.

Maschio, M., Albani, F., Baruzzi, A., Zarabla, A., Dinapoli, L., Pace, A., Pompili, A., Carapella, C. M., Occhipinti, E. and Jandolo, B. (2006). Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol., 80,97-100.

Maschio M., Dinapoli L., Sperati F., Pace A., Fabi A., Vidiri A., Muti P. (2011).Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol.,104(1),205-14.

Maschio M., Dinapoli L., Sperati F., Fabi A., Pace A., Vidiri A., Muti P. (2012). Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. J Neurooncol. 2012 Feb;106(3):651-6. Epub 2011 Aug 17. Erratum in: J Neurooncol. ,106(3), 657-9.

Maschio M., Dinapoli L., Vidiri A., Pace A., Fabi A., Pompili A., Carapella M.C., Jandolo B. (2009). The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res., 6,28,60.

Maschio, M., Dinapoli, L., Vidiri, A. and Muti, P. (2010). Rash in four patients with brain tumor-related epilepsy in monotherapy with oxcarbazepine, during radiotherapy. J Neurol ., 257,1939-1940.

Maschio M., Dinapoli L., Zarabla A., Pompili A., Carapella C.M., Pace A., Giannarelli D., Occhipinti E., Jandolo B. (2008). Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol., 86(1),61-70.

Merrell R.T., Anderson S.K., Meyer F.B., Lachance D.H. (2010). Seizures in patients with glioma treated with phenytoin and levetiracetam. J Neurosurg. ,113(6),1176-81.

Newton, H. B., Dalton, J., Goldlust, S. and Pearl, D. (2007). Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol.,84,293-296.

Novy J., Stupp R., Rossetti A.O. (2009). Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. Clin Neurol Neurosurg., 111(2),171-3.

Oberndorfer, S., Piribauer, M., Marosi, C., Lahrmann, H., Hitzenberger, P. and Grisold, W. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol., 72,255-260.

Psaras T., Will B.E., Schoeber W., Rona S., Mittelbronn M., Honegger J.B.(2008). Quantitative assessment of postoperative blood collection in brain tumor surgery under valproate medication. Zentralbl Neurochir., 69(4),165-9.

Perry J.R., Sawka C. (1996). Add-on gabapentin for refractory seizures in patients with brain tumours. Can J Neurol Sci.,23(2),128-31.

Redjal, N., Reinshagen, C., Le, A., Walcott, B. P., McDonnell, E., Dietrich, J., & Nahed, B. V. (2016). Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. Journal of Neuro-Oncology, 127(3), 505-514

Rosati A., Buttolo L., Stefini R., Todeschini A., Cenzato M., Padovani A. (2010). Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol., 67(3),343-6.

Sogawa Y., Kan L., Levy A.S., Maytal J., Shinnar S. (2009). The use of antiepileptic drugs in pediatric brain tumor patients. Pediatr Neurol., 41(3),192-4.

Tsai H.C., Wei K.C., Tsai C.N., Huang Y.C., Chen P.Y., Chen S.M., Lu Y.J., Lee S.T. (2012).Effect of valproic acid on the outcome of glioblastoma multiforme. Br J Neurosurg., 26(3),347-54.

Usery J.B., Michael L.M. 2nd, Sills A.K., Finch C.K. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol. 2010 Sep;99(2):251-60. Epub 2010 Feb 10.

van Breemen M.S., Rijsman R.M., Taphoorn M.J., Walchenbach R., Zwinkels H., Vecht C.J. (2009). Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol., 256(9),1519-26.

Van Nifterik K.A., Van den Berg J., Slotman B.J., Lafleur M.V., Sminia P., Stalpers L.J. (2012) Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. J Neurooncol.,107(1),61-7.

Vecht, C. J. and Wilms, E. B. (2010). Seizures in low- and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther., 10, 663-669.

Wagner G.L., et al. (2003). Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure, 12, 585-6.

Weller M., Gorlia T., Cairncross J.G., van den Bent M.J., Mason W., Belanger K., Brandes A.A., Bogdahn U., Macdonald D.R., Forsyth P., Rossetti A.O., Lacombe D., Mirimanoff R.O., Vecht C.J., Stupp R.(2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology., 77(12),1156-64.